List of Excipients in Branded Drug GLUCOTROL XL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	GLUCOTROL XL	glipizide	54868-4420	CELLULOSE ACETATE
Physicians Total Care Inc	GLUCOTROL XL	glipizide	54868-4420	FERRIC OXIDE RED
Physicians Total Care Inc	GLUCOTROL XL	glipizide	54868-4420	HYPROMELLOSES

GLUCOTROL XL Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Glucotrol XL is an extended-release glipizide tablet using an osmotic drug-delivery platform. Its commercial value is concentrated in generic extended-release manufacturing, excipient qualification, controlled-release formulation development, and lifecycle products rather than in brand exclusivity. The core US formulation patents associated with the original Alza osmotic platform are historical barriers and are no longer the primary obstacle to generic entry. The main technical risks are dissolution matching, membrane and orifice control, scale-up, and stability.

What is Glucotrol XL and how does its extended-release system work?

Glucotrol XL contains glipizide, a sulfonylurea used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The product is supplied in 2.5 mg, 5 mg, and 10 mg extended-release tablets.[1]

The dosage form uses an osmotic delivery mechanism. Water enters through a semipermeable membrane, hydrates the tablet core, and drives glipizide-containing material through a precision opening. The system is designed to provide controlled release over approximately 24 hours rather than the rapid exposure associated with immediate-release glipizide.[1,2]

This architecture creates a higher technical barrier than a conventional hydrophilic matrix tablet. A generic manufacturer must reproduce the complete release profile, not simply match the active ingredient and dose.

Glucotrol XL product profile

Attribute	Product information
Active ingredient	Glipizide
Therapeutic class	Sulfonylurea
Indication	Type 2 diabetes mellitus
Dosage form	Extended-release tablet
Strengths	2.5 mg, 5 mg, 10 mg
Original developer	Pfizer, using Alza osmotic technology
FDA pathway	NDA 020991
Release mechanism	Osmotic controlled-release system
Administration	Once daily, generally with breakfast
Key generic challenge	Reproducing dissolution and in vivo performance

The tablet must be swallowed whole. Crushing, splitting, or chewing can disrupt the release mechanism and increase the rate of glipizide delivery.[1]

What excipients are used in Glucotrol XL?

The Glucotrol XL label identifies excipients associated with the drug core and controlled-release coating. The principal materials include hypromellose, microcrystalline cellulose, lactose monohydrate, sodium chloride, magnesium stearate, colloidal silicon dioxide, cellulose acetate, and polyethylene glycol.[1]

The exact role of each excipient differs from its role in an immediate-release tablet.

Excipient or material	Likely functional role in the dosage form	Commercial relevance
Hypromellose	Binder, hydrophilic polymer, release-control component	Requires viscosity, substitution, particle-size, and hydration control
Microcrystalline cellulose	Filler, compactability aid, matrix support	Supports tablet strength and manufacturing robustness
Lactose monohydrate	Diluent and osmotic-core component	Impacts density, compressibility, and moisture behavior
Sodium chloride	Osmogen that drives water influx and drug displacement	High sensitivity to concentration and particle-size variation
Magnesium stearate	Lubricant	Excess use can reduce wettability and alter release
Colloidal silicon dioxide	Glidant and flow aid	Affects blend uniformity and compression
Cellulose acetate	Semipermeable membrane polymer	Controls water permeability and release rate
Polyethylene glycol	Membrane pore former or coating modifier	Affects permeability, flexibility, and coating performance

The commercial opportunity is not limited to supplying common excipients. High-value opportunities exist in excipient grades that provide tight control over viscosity, permeability, density, moisture, and particle-size distribution.

Which excipients are most important for generic Glucotrol XL?

Sodium chloride, cellulose acetate, polyethylene glycol, and hypromellose are the most formulation-critical materials.

Sodium chloride controls the osmotic pressure inside the tablet. Small changes in salt loading or particle characteristics can change water uptake and drug-release kinetics.

Cellulose acetate controls membrane permeability. Its acetyl content, molecular weight, solution properties, coating uniformity, and residual-solvent profile can materially affect dissolution.

Polyethylene glycol can function as a pore-forming or membrane-modifying component. Its molecular weight and loading influence membrane hydration and the rate at which water enters the dosage form.

Hypromellose affects core binding, hydration, viscosity, and drug mobility. A grade selected for an ordinary matrix tablet may not produce equivalent performance in an osmotic system.

What formulation strategy is required to reproduce Glucotrol XL?

A successful generic strategy should treat the product as a device-like dosage form rather than a conventional tablet. The development program should control four linked variables:

1. Core composition and mechanical strength.
2. Membrane thickness and coating uniformity.
3. Delivery-orifice size and position.
4. Dissolution performance across pH, agitation, and mechanical stress conditions.

The product's release behavior depends on the interaction among these variables. A formulation can match the nominal excipient list and still fail bioequivalence or comparative dissolution if the membrane or core process differs.

Core formulation strategy

The core should provide:

• consistent drug distribution;
• adequate mechanical strength;
• controlled osmotic pressure;
• predictable hydration;
• sufficient expansion or displacement force;
• low friability after coating and drilling.

Milled or spray-dried excipients can improve blend uniformity, but they can also change bulk density and compaction behavior. Direct compression may reduce process steps, while wet granulation can improve uniformity and tablet strength. The preferred process depends on the selected excipient grades and the target dissolution profile.

Magnesium stearate requires tight control. Excessive lubrication can create hydrophobic surfaces, reduce water ingress, and slow release. Lubrication time, lubricant concentration, and shear history should be treated as critical process parameters.

Membrane strategy

Cellulose acetate is the central membrane material. The coating process should control:

• polymer concentration;
• solvent composition;
• spray rate;
• atomization pressure;
• inlet and outlet temperatures;
• tablet-bed mixing;
• weight gain;
• residual solvent;
• membrane defects.

Polyethylene glycol can increase membrane permeability and flexibility. Its level should be optimized against coating integrity and dissolution. A membrane that is too permeable can produce premature release. A membrane that is too dense can cause incomplete delivery or excessive lag time.

Orifice strategy

The delivery opening is a critical quality attribute. Laser drilling is commercially attractive because it provides high positional accuracy and repeatability. Mechanical drilling can be used in development or lower-throughput settings but may create greater variability.

The opening must remain unobstructed during storage. Core swelling, coating deformation, crystallization, and particulate migration can affect the functional orifice.

What regulatory requirements apply to generic Glucotrol XL?

A US generic manufacturer would normally pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The application must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for extended-release products.[3]

FDA's modified-release guidance places emphasis on comparative dissolution under multiple conditions. Testing commonly evaluates different pH media, agitation speeds, and sampling intervals. The purpose is to identify formulation differences that may not appear under a single standard dissolution condition.[4]

FDA regulatory status

Glucotrol XL was approved as NDA 020991. Glipizide immediate-release and extended-release products have been available through generic competition, making the active ingredient commercially mature.[1,5]

The key regulatory distinction is between:

• an ANDA that demonstrates equivalence to the reference product; and
• a 505(b)(2) application that relies partly on existing FDA findings but proposes a different formulation, dosing regimen, delivery system, or clinical use.

A 505(b)(2) strategy may be relevant for a new once-daily glipizide product, abuse-deterrent presentation, combination product, or alternative release profile. It would involve greater development cost and regulatory risk than a conventional ANDA.

What patents protect Glucotrol XL and when did exclusivity end?

The original Glucotrol XL estate was linked to controlled-release osmotic dosage-form technology developed by Alza. Historical US patents associated with this technology include US Patent No. 5,464,633, issued in 1995 and directed to controlled-release drug-delivery systems.[6]

The original patent term would have expired in the early 2010s, subject to patent-term adjustment, terminal disclaimers, and any applicable extensions. The core platform patents therefore do not provide a current commercial barrier comparable to a recently launched small-molecule product.

Protection category	Commercial assessment
Active ingredient patent	Historical; glipizide is an established generic active
Original osmotic platform patents	Historical and generally expired
Formulation patents	Must be reviewed against current Orange Book listings
Method-of-use patents	Limited relevance if directed to established type 2 diabetes use
Manufacturing patents	Potentially relevant to a specific process, but avoidable if independently developed
Regulatory exclusivity	No current brand-level exclusivity is expected for this mature product

What is the Orange Book status of Glucotrol XL?

The Orange Book remains the controlling source for current FDA-listed patents and regulatory exclusivity. A commercial diligence review should distinguish between patents historically associated with the product and patents currently listed against NDA 020991.[5]

For a mature product such as Glucotrol XL, the principal entry route is typically an ANDA supported by Paragraph III certification if listed patent protection remains, or Paragraph IV certification where an applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The value of a Paragraph IV strategy depends on the current Orange Book listing, the number of approved ANDAs, and whether the reference sponsor has enforceable remaining claims.

Which companies are challenging Glucotrol XL, and what litigation affects the product?

Generic glipizide extended-release products have entered the US market, demonstrating that the core formulation and regulatory barriers are commercially navigable. Public product databases identify multiple generic suppliers for glipizide extended-release tablets, although supplier status and marketing activity can change over time.[5,7]

The historical patent risk was concentrated in the osmotic dosage-form platform. Current litigation risk is more likely to arise from:

• a newly listed formulation patent;
• a process patent covering a specific coating or drilling sequence;
• Paragraph IV litigation involving a later entrant;
• manufacturing-site or supply-chain disputes;
• product liability claims related to altered release after tablet damage.

No current settlement should be assumed from historical patent expiry alone. Each ANDA entrant must assess its certification, any 30-month stay, litigation outcome, and settlement restrictions separately.

What commercial opportunities exist in the Glucotrol XL excipient market?

The largest opportunity is in qualified, high-consistency excipient supply for generic extended-release products. Commodity pricing limits the value of lactose, microcrystalline cellulose, and magnesium stearate unless the supplier can provide superior control or integrated technical support.

High-value excipient opportunities

Cellulose acetate membrane systems

Suppliers can differentiate through:

• controlled acetyl content;
• low batch-to-batch permeability variation;
• coating-grade particle and solution behavior;
• low residual impurities;
• validated solvent compatibility;
• technical support for scale-up.

Cellulose acetate is the most strategically differentiated material in the membrane system.

Pharmaceutical-grade polyethylene glycol

PEG suppliers can target coating developers that need reproducible molecular weight, low peroxide content, and stable pore-forming behavior. A validated PEG grade can reduce reformulation risk during scale-up.

High-performance hypromellose

Hypromellose suppliers can offer grades optimized for osmotic cores rather than conventional matrix tablets. Useful attributes include predictable hydration, low variability in viscosity, and controlled particle-size distribution.

Integrated excipient systems

A prequalified excipient blend containing diluent, osmogen, binder, and flow aid could reduce development time for generic manufacturers. The supplier would need to provide design-space data, compatibility studies, and dissolution-support packages.

Coating and manufacturing services

Contract manufacturers with osmotic coating, laser drilling, and in-process inspection capabilities can compete for development and commercial supply. The equipment requirement creates a higher barrier than standard tablet compression.

How strong is the patent estate for Glucotrol XL?

The current patent estate is commercially weak at the core-product level because the active ingredient is old and the original osmotic platform patents are historical. The stronger barriers are technical and operational.

Barrier	Relative strength	Reason
Active ingredient IP	Low	Mature generic compound
Original platform patents	Low	Historical patents have generally expired
Exact formulation replication	Medium	Requires extensive development and testing
Membrane coating process	Medium to high	Scale-up and uniformity can be difficult
Laser-drilled delivery system	Medium	Equipment and process controls are required
Excipient supply qualification	Medium	Changes can affect dissolution and comparability
Clinical differentiation	Low	Established therapeutic class with inexpensive alternatives

A company with a validated osmotic manufacturing platform has a stronger position than a company relying only on standard tablet capabilities. The most defensible assets are process know-how, dissolution data, equipment qualification, and reliable supply of critical membrane materials.

How does Glucotrol XL compare with immediate-release glipizide and other diabetes drugs?

Product category	Main advantage	Main limitation	Excipient opportunity
Glucotrol XL and generic glipizide ER	Once-daily dosing and controlled exposure	Hypoglycemia risk; complex manufacturing	Osmotic membranes, osmogen systems
Immediate-release glipizide	Low-cost and simple formulation	Multiple daily dosing may be required	Conventional tablet excipients
Metformin extended release	Large patient base and broad generic demand	Matrix dissolution and gastrointestinal tolerability	HPMC, polymer matrices, low-dose variability
DPP-4 inhibitors	Lower hypoglycemia risk than sulfonylureas	Higher cost and active-product patent history for some products	Direct-compression and film-coating systems
SGLT2 inhibitors	Cardiovascular and renal positioning for some products	More complex clinical and commercial competition	Coating, stability, and combination-product excipients

Glucotrol XL is unlikely to support premium pricing against low-cost generic alternatives unless a new product offers a meaningful dosing, tolerability, adherence, or combination-product advantage.

What generic launch scenarios exist for Glucotrol XL?

Three scenarios are commercially realistic:

1. Standard ANDA entry: A manufacturer matches the reference product's dosage form, strengths, and release profile.
2. Second-source or contract-manufacturing entry: An established generic sponsor uses a specialist osmotic manufacturer to reduce development and capital requirements.
3. Reformulated 505(b)(2) product: A sponsor develops a new delivery profile, fixed-dose combination, or differentiated administration method.

The first scenario has the lowest regulatory risk but the highest price competition. The second offers an opportunity for excipient suppliers and contract development organizations. The third may support higher pricing but requires clinical and regulatory investment.

What revenue exposure does Glucotrol XL create for Pfizer and suppliers?

Pfizer does not report Glucotrol XL revenue as a separate public line item. The commercial value of the brand is therefore not directly measurable from Pfizer's consolidated disclosures.[8]

For excipient and manufacturing companies, exposure is better assessed through annual demand for generic glipizide extended-release products, the number of approved ANDA holders, and the share of supply produced with osmotic technology. Demand is recurring but modest relative to high-volume immediate-release or metformin products. The strongest commercial case is usually a platform strategy that serves multiple controlled-release products rather than Glucotrol XL alone.

Key Takeaways

• Glucotrol XL is a once-daily osmotic glipizide extended-release tablet.
• Its critical excipients include cellulose acetate, polyethylene glycol, sodium chloride, hypromellose, microcrystalline cellulose, lactose, magnesium stearate, and colloidal silicon dioxide.
• Sodium chloride and the cellulose acetate membrane are central to release control.
• The original osmotic platform patent barriers are historical; current risk is concentrated in formulation replication and manufacturing execution.
• Generic entry is commercially feasible through an ANDA, but dissolution matching and scale-up are demanding.
• Excipient suppliers have the strongest opportunities in membrane polymers, osmogen systems, high-consistency hypromellose, and integrated development packages.
• Pfizer does not separately disclose Glucotrol XL revenue.
• A 505(b)(2) strategy is possible for a differentiated delivery system but carries materially higher development risk than a conventional generic.

FAQs

Can a conventional hydrophilic matrix replace the Glucotrol XL osmotic system?

Possibly, but a different release mechanism would generally require development against the reference product and may not qualify as a straightforward formulation substitution. The sponsor would need to establish bioequivalence and acceptable comparative dissolution.

Which excipient creates the greatest supply-chain risk?

Cellulose acetate is the most likely critical material because membrane composition and permeability directly affect product performance. Specialized hypromellose and pharmaceutical-grade PEG can also create qualification risks.

Is Glucotrol XL suitable for a fixed-dose combination product?

It may be technically suitable, but combining glipizide with another antidiabetic agent would require compatibility, release-profile, dose, and regulatory assessment. A fixed-dose product would more likely require a 505(b)(2) pathway or a new application.

What manufacturing equipment is needed for a Glucotrol XL-type product?

Commercial production generally requires controlled tablet compression, solvent or aqueous membrane coating, precision orifice formation, automated inspection, and extended-release dissolution testing. Laser-drilling capability can be important for process consistency.

Can excipient changes be made after generic approval?

Yes, but post-approval changes must be evaluated under FDA's scale-up and post-approval change framework. For an osmotic product, changes to polymer grade, salt particle size, coating weight, or lubricant level can require comparative dissolution and additional regulatory support.

References

1. Pfizer Inc. (2019). Glucotrol XL (glipizide) extended-release tablets: Prescribing information. U.S. Food and Drug Administration labeling repository.
2. Theeuwes, F. (1984). Elementary osmotic pump. Journal of Pharmaceutical Sciences, 73(12), 1793-1799.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals.
4. U.S. Food and Drug Administration. (2015). Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Guidance for industry.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
6. Alza Corporation. (1995). Controlled-release drug-delivery system. U.S. Patent No. 5,464,633.
7. National Library of Medicine. (2024). DailyMed: Glipizide extended-release tablet labeling.
8. Pfizer Inc. (2024). Annual report 2023.